Wells Fargo
APLS

Wells Fargo’s Apellis Pharmaceuticals APLS Stock Holding History

Wells Fargo’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,700
Closed -$1.48M – 7451
2022
Q3 		$1.48M Buy
+21,700
New +$1.28M ﹤0.01% 2963

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wells Fargo's APLS Position: Q1 2026 in Review

Wells Fargo reduced its Apellis Pharmaceuticals (APLS) stake by 92% in Q1 2026, selling an estimated $2.05M and leaving 8,592 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #4353.

Wells Fargo first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. The position peaked at $18.1M in Q2 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Wells Fargo held 8,592 shares of Apellis Pharmaceuticals worth $346K as of Q1 2026.
  • Wells Fargo sold 95,223 Apellis Pharmaceuticals shares in Q1 2026, an estimated $2.05M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4353 holding.
  • Wells Fargo first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Wells Fargo's Apellis Pharmaceuticals position peaked at $18.1M in Q2 2025.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.